| Pfizer Halts Heart Failure Drug Trial Early on Good News Derek Lowe submits: Pfizer (PFE) was able to announce some good news today - their trial of Inspra (eplerenone) for patients with a particular combination of heart failure symptoms. The trial was halted early, but (for once) because the endpoints were reached so early that it would have been unethical to continue the placebo arm. It's always nice to hear about one of those; we don't get them that often. The drug is an aldosterone antagonist which had already been approved several years ago for heart failure and hypertension, so it's not really a surprise that it worked in this population. But you never know, and Pfizer wanted to be able to get specifically recommended for patients of this type. And that they will.Complete Story » seekingalpha.com |
Prostate Cancer Drug Gets Approval The FDA approved Jevtana, a Sanofi-Aventis chemotherapy drug used in combination with the steroid prednisone to treat men with prostate cancer. online.wsj.com |
New Hepatitis Therapy Could Be Vertex's Windfall The Burrill Report submits: By Michael FitzhughVertex Pharmaceutical (VRTX) says a new trial shows that its late-stage hepatitis C therapy, telaprevir, can help some people tackle the virus in half the time the current treatment takes. A quicker cure, one slashing typical treatment times to 24 weeks from 48 weeks, could help millions of infected people stick to their treatment regimens and represent a windfall for Vertex. Complete Story » seekingalpha.com |
BioClinica names Johnson chief technology officer [AP] - Clinical trial services company BioClinica Inc. said Wednesday it named Garry D. Johnson to the newly created position of chief technology officer. us.rd.yahoo.com |
Neurocrine Biosciences Seen Running Out of Gas optionMONSTER submits: By David Russell Neurocrine Biosciences (NBIX) has made a big move, and now the bulls are throwing in the towel.Complete Story » seekingalpha.com |